In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vermillion raises $43mm to come out of Chapter 11

Executive Summary

Diagnostics company Vermillion grossed $43mm through the sale of 2.3mm common shares at $18.49 each (an 8% discount) to an undisclosed group of investors. The company will use the proceeds to repay debt, in particular a debtor-in-possession agreement with partner Quest Diagnostics, and hopes to restructure and emerge from its Chapter 11 bankruptcy filing in early 2010.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies